Available Technologies
# of Displayed Technologies: 1 / 1
Sustained Release Microparticles for the Treatment of Ocular Diseases
TS-038312 — A novel, intravitreal microparticle injection capable of controlled-release of protein therapies (including anti-VEGF) for tunable periods of 6-12 months after injection for the treatment of age-related macular degeneration.
Age-related macular degeneration (AMD) is the leading cause of blindness in individuals 65 and older and is the third leading cause of blindness worldwide. Wet AMD is characterized by abnormal growth of leaky blood vessels leading to damage to the macula of the retina resulting in vision loss and …
- College: College of Engineering (COE)
- Inventors: Jiang, Pengfei; Ohr, Matthew; Reilly, Katelyn
- Licensing Officer: Schworer, Adam
